- Drugs
- Transcatheter Embolization
- Ultrasound-guided Compression
- Surgery
Arteriovenous Fistula Treatment Market Size was valued at USD 346.7 million in 2022 and is poised to grow at a CAGR of 6.46% over 2023-2029. An arteriovenous fistula is an abnormal connection or passageway between an artery and a vein that may be congenital, surgically created for hemodialysis treatments, or acquired due to a pathological process, such as trauma or erosion of an aortic aneurysm. Based on the treatment type, Transcatheter embolization is anticipated to dominate the market share over the forecast period. According to the American Heart Association, the crude incidence rates between 2009 and 2019 were 2.040 per 1,00,000 person-years for all arteriovenous fistulas. The growing awareness and development of new treatment methods will act as the growth drivers for the market, whereas the lack of awareness regarding arteriovenous fistula treatment might have a negative impact on the market. The limited treatment methods and the highly affected population due to the disease are huge opportunities for the growth of the market.
Arteriovenous Fistula Treatment Market Summary
Study Period
2023-29
Base Year
2022
CAGR
6.4%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Arteriovenous Fistula Treatment Market Dynamics
The arteriovenous fistula treatment market is expected to expand as key players in the market are investing largely in new treatment methods such as photodynamic therapy, antiangiogenic therapy, and other sclerotherapy methods. Furthermore, there have been growing FDA approvals for noninvasive devices for arteriovenous fistula creation. Thus, the growing geriatric population, increasing prevalence of end-stage renal disease, favorable reimbursement policies, and rising healthcare expenditure will drive the arteriovenous fistula treatment market growth over the forecast period.
North America Got Significant Share
Arteriovenous Fistula Treatment Market Regional Analysis
The Arteriovenous Fistula Treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. During a 10-year study period done by the American Heart Association, the crude incidence rates for cerebral arteriovenous malformations (CAVMs) was 0.805, for intracranial dural arteriovenous fistulas (DAVFs) WAS 1.044, and 0.177 for (spinal arteriovenous fistulas) SAVs. According to a research report, the rate of arteriovenous fistula has the highest rates in the Northeast and the lowest in the Southeast of the USA. The North America Arteriovenous Fistula Treatment market is expected to dominate the market over the forecast period, due to the successful measures taken by the US government to provide the market with novel therapies for arteriovenous fistula, and also the presence of leading pharmaceutical players placed in the region have been positively impacting the market growth. Moreover, owing to the rising awareness of fistula treatment in the Europe region, the European market is also expected to witness growth over the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The arteriovenous fistula treatment market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Arteriovenous Fistula Treatment Market Segmentation
By Treatment Type
By Type
- Arteriovenous Fistulas
- Dural
- Peripheral
- Pial or Cerebral
- Other Fistula Types
By Geography
- North America
- Europe
- The Asia Pacific
- Latin America
- MEA
- Rest of MEA
Frequently Asked Questions
The Arteriovenous Fistula Treatment market was valued at USD 346.7 million in 2022 and is expected to grow at a 6.46% CAGR over the forecast period 2023 – 2029.
The limited treatment methods and the highly affected population due to the disease are the key opportunities for the Arteriovenous Fistula Treatment market.
The growing awareness and development of new treatment methods are the growth drivers in the Arteriovenous Fistula Treatment market.
Becton Dickinson, Medtronic, Cook Medical, Teleflex Incorporated, Fresenius Medical Care AG & Co. KGaA, NxStage Medical, Poly Medicure Limited, and Braun Melsungen AG are a few companies operating in the Arteriovenous Fistula Treatment market.
- Becton Dickinson
- Medtronic
- Cook Medical
- Teleflex Incorporated
- Fresenius Medical Care AG & Co. KGaA
- NxStage Medical
- Poly Medicure Limited
- Braun Melsungen AG